Visterra, Inc.

Visterra, Inc. operates as a biologics research and early-stage clinical development organization developing therapies for immune-mediated and other hard-to-treat diseases. The company develops biologic therapies with a focus on nephrology, rheumatology, transplant immunology, and neurology. It conducts research, preclinical, and early-stage clinical development of monoclonal antibodies and other biologics, including investigational products such as sibeprenlimab (VIS649) for IgA nephropathy. The company utilizes computational, artificial intelligence, and experimental research methods, as well as protein engineering platforms such as Hierotope. It provides clinical trial management, process development, scale-up, and transfer of drug substance processes as part of its pharmaceutical sciences and technology services. The company was founded in 2007 and is based in Waltham, Massachusetts.